On December 1, 2022 Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today publication of abstracts by ESMO (Free ESMO Whitepaper)-IO showing that at the time of abstract data cutoff, Compugen’s COM701 (anti-PVRIG) in dual and triple combination with nivolumab ± BMS-986207 demonstrated preliminary anti-tumor activity and immune activation in platinum resistant ovarian cancer patients and was well tolerated (Press release, Compugen, DEC 1, 2022, View Source [SID1234624643]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Company plans to host a conference call and webcast on Wednesday, December 7, 2022, at 8:30 AM ET to review its preliminary clinical data from dual and triple combination of COM701+ nivolumab ± BMS-986207 in platinum resistant ovarian cancer patients and its COM701 ± nivolumab in metastatic NSCLC patients to be presented at ESMO (Free ESMO Whitepaper)-IO, December 8, 2022, Geneva, Switzerland. Abstracts are available today on the ESMO (Free ESMO Whitepaper)-IO website and posters with longer follow-up data will be available on the ESMO (Free ESMO Whitepaper)-IO virtual platform, in the e-Poster section on December 6, 2022.
"Platinum resistant ovarian cancer patients are in urgent need of new treatment options. Current standard of care, single agent chemotherapy, is characterized by toxicity and low activity and recently approved ADC therapy is restricted to a subset of the population and limited by ocular toxicity. So far immune checkpoint inhibitors showed limited activity especially in PD-L1 low expressors, where the unmet need is the greatest," said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen. "At ESMO (Free ESMO Whitepaper)-IO we will present encouraging preliminary anti-tumor activity supported by immune activation and favorable safety profile following the dual and triple blockade of PVRIG, PD-1 ± TIGIT in platinum resistant ovarian cancer patients. The full data to be presented at the conference remain under embargo until December 6, 2022 and will contain longer follow up. We are looking forward to discussing this data along with our NSCLC data which will also be presented at ESMO (Free ESMO Whitepaper)-IO, in addition to our plans going forward, during our investor call on December 7, 2022."
The abstracts are published today on the ESMO (Free ESMO Whitepaper)-IO website, and the publication section of Compugen’s website. On December 6, 2022, posters with longer follow-up data will be available on the e-Poster section of the ESMO (Free ESMO Whitepaper)-IO virtual platform and the publication section of Compugen’s website.